《半新股》中慧生物(02627.HK)曾漲近10%後倒跌 上市四日累漲近2.9倍
本周一(11日)上市的疫苗公司中慧生物-B(02627.HK)今早(14日)高開1.5%後,初段曾升9.6%高見57.2元,隨後倒跌,最新報50.3元,跌3.64%,成交226.28萬股,涉資1.19億元。
該股首日掛牌收報33.28元,較上市價12.9元大幅高出約158%。以現價50.3元計,較上市價高出近2.9倍。該股香港公開發售接獲4,007.64倍認購,晉身今年以來超購王第三位。集資淨額約3.83億元。由中信証券及招銀國際擔任聯席保薦人。
集團日前公布,旗下四價流感病毒亞單位疫苗(商品名「慧爾康欣」),獲納入今年度國家商業健康保險創新藥品目錄通過初步審查的名單,成為當中的唯一一款疫苗產品。
該產品已於2023年5月獲國家藥監局新藥申請(NDA)批准,可用於三歲及以上人群,是截至2025年7月21日在中國獲批的首款且唯一一款四價流感病毒亞單位疫苗,旨在針對甲型流感病毒H1N1和H3N2亞型,以及乙型流感病毒Yamagata和Victoria譜系提供廣泛保護,具有保護全面、組分抗原純度高、不良反應風險低等優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.